Inna A. Novikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Inna A. Novikova has a total of 341 co-authors. Here are the top co-authors by number of shared publications:
- Elena Yu. Zlatnik
National Medical Research Center of Oncology, Ministry of Health of Russia
39 shared publications - Oleg Ivanovich Kit
National Medical Research Centre for Oncology, Rostov-on-Don, Russia
36 shared publications - Svetlana Yu. Filippova
National Medical Research Center of Oncology, Ministry of Health of Russia
24 shared publications - Aleksandr B. Sagakyants
National Medical Research Centre for Oncology
18 shared publications - Irina V. Mezhevova
Национальный медицинский исследовательский центр онкологии Министерства здравоохранения Российской Федерации
18 shared publications - Sofia Vladimorovna Timofeeva
National Medical Research Centre for Oncology
17 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Kazakh University of Technology and Business in Вестник КазУТБ
- Vol. 1 (30)
ОТАНДЫҚ СЕЛЕКЦИЯЛЫ БИДАЙ ДӘНІНЕН СЫРАЛЫҚ УЫТ ӨНДІРУГЕ АРНАЛҒАН УЫТ ӨСІРУ РЕЖИМДЕРІН ТАҢДАУ
Мақалада Қазақстан Республикасының отандық селекциясымен шығарылған бидай сорттарынан бидай уытын өндірудің теориялық және эксперименттік аспектілері қарастырылып, оны сыра қайнату саласында қолданудың мақсатқа сәйкестігі негізделді. Зерттеудің өзектілігі жергілікті дәнді дақыл шикізатын пайдалану арқылы сыра қайнатудың шикізат базасын кеңейту және импорттық уытқа тәуелділікті төмендету қажеттілігімен айқындалады. Зерттеу нысандары ретінде дәннің физика-химиялық және технологиялық сипаттамалары бойынша ерекшеленетін қазақстандық селекциялы жұмсақ бидай сорттары - Матай, Ертіс және Тәуелсіздік таңдап алынды. Жұмыста ғылыми-техникалық және нормативтік әдебиеттерді талдау әдістері, сонымен қатар дән мен уыттың сапасын бағалаудың жалпы қабылданған физика-химиялық, биохимиялық және технологиялық әдістері қолданылды. Эксперименттік бөлім бидайды уыт өсірудің әртүрлі температуралық-уақыттық режимдерін таңдау мен салыстыруды, ылғал жинақталуының динамикасын, азотты заттар мөлшерінің және бос аминді азоттың өзгерісін бақылауды қамтыды. Зерттелген бидай сорттарының барлығы қанағаттанарлық физиологиялық белсенділікке ие екені анықталды және оларды уыт өндірісі үшін шикізат ретінде қарастыруға болады. Бидай уытын алу үшін ең қолайлы Тәуелсіздік сорты болып шықты, ол ақуыз мөлшерінің және дәннің шынылығының орташа деңгейімен сипатталады. Уыт өсіру температурасы ақуыздық гидролиздің қарқындылығына және ашытқылар үшін уыттың қоректік құндылығын айқындайтын еркін аминді азоттың жиналуына елеулі әсер ететіні көрсетілді. Алынған нәтижелер технологиялық көрсеткіштері сыра қайнату саласының талаптарына сәйкес келетін бидай уытын өндіру мүмкіндігін растайды және отандық шикізат негізінде бидай сырасын өндіру технологияларын әзірлеуде пайдаланылуы мүмкін.
- 30 March 2026
- Published by Kazakh University of Technology and Business in Вестник КазУТБ
- Vol. 1 (30)
Open AccessОТАНДЫҚ СЕЛЕКЦИЯЛЫ БИДАЙ ДӘНІНЕН СЫРАЛЫҚ УЫТ ӨНДІРУГЕ АРНАЛҒАН УЫТ ӨСІРУ РЕЖИМДЕРІН ТАҢДАУ
Мақалада Қазақстан Республикасының отандық селекциясымен шығарылған бидай сорттарынан бидай уытын өндірудің теориялық және эксперименттік аспектілері қарастырылып, оны сыра қайнату саласында қолданудың мақсатқа сәйкестігі негізделді. Зерттеудің өзектілігі жергілікті дәнді дақыл шикізатын пайдалану арқылы сыра қайнатудың шикізат базасын кеңейту және импорттық уытқа тәуелділікті төмендету қажеттілігімен айқындалады. Зерттеу нысандары ретінде дәннің физика-химиялық және технологиялық сипаттамалары бойынша ерекшеленетін қазақстандық селекциялы жұмсақ бидай сорттары - Матай, Ертіс және Тәуелсіздік таңдап алынды. Жұмыста ғылыми-техникалық және нормативтік әдебиеттерді талдау әдістері, сонымен қатар дән мен уыттың сапасын бағалаудың жалпы қабылданған физика-химиялық, биохимиялық және технологиялық әдістері қолданылды. Эксперименттік бөлім бидайды уыт өсірудің әртүрлі температуралық-уақыттық режимдерін таңдау мен салыстыруды, ылғал жинақталуының динамикасын, азотты заттар мөлшерінің және бос аминді азоттың өзгерісін бақылауды қамтыды. Зерттелген бидай сорттарының барлығы қанағаттанарлық физиологиялық белсенділікке ие екені анықталды және оларды уыт өндірісі үшін шикізат ретінде қарастыруға болады. Бидай уытын алу үшін ең қолайлы Тәуелсіздік сорты болып шықты, ол ақуыз мөлшерінің және дәннің шынылығының орташа деңгейімен сипатталады. Уыт өсіру температурасы ақуыздық гидролиздің қарқындылығына және ашытқылар үшін уыттың қоректік құндылығын айқындайтын еркін аминді азоттың жиналуына елеулі әсер ететіні көрсетілді. Алынған нәтижелер технологиялық көрсеткіштері сыра қайнату саласының талаптарына сәйкес келетін бидай уытын өндіру мүмкіндігін растайды және отандық шикізат негізінде бидай сырасын өндіру технологияларын әзірлеуде пайдаланылуы мүмкін.
- 16 February 2026
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (4) , 6046-6060
Clinico-Morphological and Genetic Features of Colorectal Cancer in Multiple Primary Cancers Cases
- 16 February 2026
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (4) , 6046-6060
Clinico-Morphological and Genetic Features of Colorectal Cancer in Multiple Primary Cancers Cases
- Open Access
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4565
Search for diagnostic microRNAs for brain tumor identification using a low-temperature plasma bank
Aim . To assess the level of circulating small non-coding ribonucleic acids (microRNAs), previously identified as differentially expressed in next-generation sequencing (NGS) profiles of various brain tumor types, using a validation cohort formed from a low-temperature plasma bank. Material and methods . Plasma bioarchiving was performed on patients treated for brain tumors at the National Medical Research Center of Oncology from April 2018 to December 2024. Reverse transcription-polymerase chain reaction (RT-PCR) was used to determine the levels of 10 microRNAs in plasma samples from 40 individuals. Participants were divided into five groups of eight individuals as follows: those diagnosed with glioblastoma, astrocytoma, oligodendroglioma, benign meningioma, and healthy controls. The study groups included 17 women and 15 men, with a median age of 52,5 years. The control group included seven women and one man, with a median age of 53 years. Results . Plasma levels of miR-30c-5p, miR-128-3p, miR-186-5p, miR-194-5p, miR-484, miR-19b-3p, miR-431-5p, miR-3168, let-7c-5p, and miR-363-3p were determined using NGS data from 58 plasma samples (Gvaldin, 2024). The validation cohort revealed differential expression changes for four microRNAs (miR-128-3p, miR-194-5p, miR-19b-3p, and miR-363-3p) across the study groups. Conclusion . Differential expression of circulating miR-128-3p, miR-194-5p, miR-19b-3p, and miR-363-3p is associated with brain tumor oncogenesis and can be used for their diagnosis.
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4565
Open AccessSearch for diagnostic microRNAs for brain tumor identification using a low-temperature plasma bank
Aim . To assess the level of circulating small non-coding ribonucleic acids (microRNAs), previously identified as differentially expressed in next-generation sequencing (NGS) profiles of various brain tumor types, using a validation cohort formed from a low-temperature plasma bank. Material and methods . Plasma bioarchiving was performed on patients treated for brain tumors at the National Medical Research Center of Oncology from April 2018 to December 2024. Reverse transcription-polymerase chain reaction (RT-PCR) was used to determine the levels of 10 microRNAs in plasma samples from 40 individuals. Participants were divided into five groups of eight individuals as follows: those diagnosed with glioblastoma, astrocytoma, oligodendroglioma, benign meningioma, and healthy controls. The study groups included 17 women and 15 men, with a median age of 52,5 years. The control group included seven women and one man, with a median age of 53 years. Results . Plasma levels of miR-30c-5p, miR-128-3p, miR-186-5p, miR-194-5p, miR-484, miR-19b-3p, miR-431-5p, miR-3168, let-7c-5p, and miR-363-3p were determined using NGS data from 58 plasma samples (Gvaldin, 2024). The validation cohort revealed differential expression changes for four microRNAs (miR-128-3p, miR-194-5p, miR-19b-3p, and miR-363-3p) across the study groups. Conclusion . Differential expression of circulating miR-128-3p, miR-194-5p, miR-19b-3p, and miR-363-3p is associated with brain tumor oncogenesis and can be used for their diagnosis.
- 14 January 2026
- Published by Folium Publishing Company in Химико-фармацевтический журнал
- Vol. 59 (12) , 3-9
Эффект артемизинина и его производных на линии клеток рака предстательной железы: мини-обзор
Настоящая работа посвящена комплексному исследованию артемизинина и его производных как перспективных веществ в терапии рака предстательной железы (РПЖ). Учитывая статистику ВОЗ и GLOBOCAN, отмечающую стабильно высокое распространение РПЖ среди мужского населения планеты, поиск новых лечебных подходов для этой нозологии приобретает особую значимость. Мы проанализировали доступные научные данные о множестве механизмов, посредством которых артемизинин действует на клетки РПЖ, включая индукцию апоптоза, ингибирование пролиферации и инвазивных способностей, подавление воспаления и ангиогенеза. Проведенные лабораторные эксперименты подтвердили способность артемизинина эффективно уничтожать раковые клетки и демонстрировать избирательность по отношению к здоровым тканям. Особое внимание уделено вопросам совместимости артемизинина с общепринятыми методами терапии, таким как применение паклитаксела, что открывает возможность эффективного сочетания препаратов для улучшения терапевтического результата. Кроме того, нами детально рассмотрен эпигенетический аспект действия артемизинина, включая его влияние на процессы метилирования ДНК и регуляцию генов, контролирующих рост и развитие опухоли. При этом обозначены ограничения и нерешенные проблемы, касающиеся оптимального способа доставки артемизинина, выбора безопасной и эффективной доз, предотвращения побочных эффектов и долговременных последствий терапии. Подчеркивая многогранность действия артемизинина, мы считаем, что дальнейшее изучение позволит значительно расширить арсенал средств борьбы с РПЖ и внести существенный вклад в улучшение показателей выживаемости пациентов.
- 14 January 2026
- Published by Folium Publishing Company in Химико-фармацевтический журнал
- Vol. 59 (12) , 3-9
Эффект артемизинина и его производных на линии клеток рака предстательной железы: мини-обзор
Настоящая работа посвящена комплексному исследованию артемизинина и его производных как перспективных веществ в терапии рака предстательной железы (РПЖ). Учитывая статистику ВОЗ и GLOBOCAN, отмечающую стабильно высокое распространение РПЖ среди мужского населения планеты, поиск новых лечебных подходов для этой нозологии приобретает особую значимость. Мы проанализировали доступные научные данные о множестве механизмов, посредством которых артемизинин действует на клетки РПЖ, включая индукцию апоптоза, ингибирование пролиферации и инвазивных способностей, подавление воспаления и ангиогенеза. Проведенные лабораторные эксперименты подтвердили способность артемизинина эффективно уничтожать раковые клетки и демонстрировать избирательность по отношению к здоровым тканям. Особое внимание уделено вопросам совместимости артемизинина с общепринятыми методами терапии, таким как применение паклитаксела, что открывает возможность эффективного сочетания препаратов для улучшения терапевтического результата. Кроме того, нами детально рассмотрен эпигенетический аспект действия артемизинина, включая его влияние на процессы метилирования ДНК и регуляцию генов, контролирующих рост и развитие опухоли. При этом обозначены ограничения и нерешенные проблемы, касающиеся оптимального способа доставки артемизинина, выбора безопасной и эффективной доз, предотвращения побочных эффектов и долговременных последствий терапии. Подчеркивая многогранность действия артемизинина, мы считаем, что дальнейшее изучение позволит значительно расширить арсенал средств борьбы с РПЖ и внести существенный вклад в улучшение показателей выживаемости пациентов.
- Open Access
- 1 January 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1)
A Rare Case Report of the В-Cell Chronic Lymphocytic Leukemia Diagnosis During the Stage of Transformation into Diffuse Large B-cell Lymphoma (Richter Syndrome)
This paper reports a rare case of diagnosing В-cell chronic lymphocytic leukemia (CLL) during the stage of transformation into diffuse large B-cell lymphoma (Richter syndrome). A 62-year-old patient showed a local increase in the right upper jugular lymph node confirmed by PET/CT. By immunomorphological analysis of tumor tissue from the resected lymph node, diffuse large B-cell lymphoma (CD20+, CD23+, CD5+, BCL2+, BCL6+, LEF1+, Cyclin D1–, Ki-67 70 %) was diagnosed. At the same time, the peripheral blood test and myelogram revealed an increased absolute lymphocyte count and morphological heterogeneity of lymphocytes with predominating same-type small and medium-sized cells with rounded nuclei as well as abnormal larger cells with irregular-shaped nuclei and basophilic vacuolated cytoplasm. By flow cytometry, the immunophenotype of tumor В-lymphocytes corresponded to СD5-positive mature В-cell lymphoid tumor, mostly to В-CLL. According to the analysis of the bone marrow core biopsy sample, morphological pattern and immunophenotype of tumor cells (CD79+, CD5+/–, CD23+, LEF1+, Ki-67 5 %) were consistent with the diagnosis of В-cell small lymphocytic lymphoma/В-CLL. So, based on the total of obtained data, patient was diagnosed with small lymphocytic lymphoma/В-CLL transformation into diffuse large B-cell lymphoma (Richter syndrome) with a lesion in the right upper jugular lymph node.
- 1 January 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1)
Open AccessA Rare Case Report of the В-Cell Chronic Lymphocytic Leukemia Diagnosis During the Stage of Transformation into Diffuse Large B-cell Lymphoma (Richter Syndrome)
This paper reports a rare case of diagnosing В-cell chronic lymphocytic leukemia (CLL) during the stage of transformation into diffuse large B-cell lymphoma (Richter syndrome). A 62-year-old patient showed a local increase in the right upper jugular lymph node confirmed by PET/CT. By immunomorphological analysis of tumor tissue from the resected lymph node, diffuse large B-cell lymphoma (CD20+, CD23+, CD5+, BCL2+, BCL6+, LEF1+, Cyclin D1–, Ki-67 70 %) was diagnosed. At the same time, the peripheral blood test and myelogram revealed an increased absolute lymphocyte count and morphological heterogeneity of lymphocytes with predominating same-type small and medium-sized cells with rounded nuclei as well as abnormal larger cells with irregular-shaped nuclei and basophilic vacuolated cytoplasm. By flow cytometry, the immunophenotype of tumor В-lymphocytes corresponded to СD5-positive mature В-cell lymphoid tumor, mostly to В-CLL. According to the analysis of the bone marrow core biopsy sample, morphological pattern and immunophenotype of tumor cells (CD79+, CD5+/–, CD23+, LEF1+, Ki-67 5 %) were consistent with the diagnosis of В-cell small lymphocytic lymphoma/В-CLL. So, based on the total of obtained data, patient was diagnosed with small lymphocytic lymphoma/В-CLL transformation into diffuse large B-cell lymphoma (Richter syndrome) with a lesion in the right upper jugular lymph node.
- Open Access
- 17 December 2025
- Published by FSBEI HE Voronezh State University of Engineering Technologies in Proceedings of the Voronezh State University of Engineering Technologies
- Vol. 87 (3) , 129-134
Features of beer beverage technology using non-traditional raw materials
The aim of this study is to develop a technology for producing beverages using non-traditional raw materials for consumers with gastrointestinal disorders and to investigate the physicochemical properties of the resulting products. A comprehensive approach was used to conduct the study, including an analysis of scientific literature, including the potential for beer consumption by people with gastrointestinal issues, and an examination of functional beverage production technology. The study involved beverage samples produced using quinoa malt, Jerusalem artichoke powder, and berry and vegetable juices. The technological processes for producing beer beverages with an alcohol content of 2.5-3.0% by volume were studied. Physicochemical studies, namely, extract content, color, active (pH 5.2), and titratable acidity, demonstrated that all developed beverage samples meet regulatory standards for this type of product. The organoleptic properties of the beverages were found to have a balanced flavor profile, owing to the inclusion of quinoa malt, Jerusalem artichoke powder, and berry and vegetable juices such as apricot, lingonberry, pumpkin, and carrot. The study demonstrated the potential of using quinoa malt and Jerusalem artichoke powder to create specialized food products. The developed technology not only addresses the needs of certain population groups but also expands the product range by producing functional, gluten-free beverages with an improved nutrient profile. Further research could focus on optimizing flavor balance, studying the stability and shelf life of these products, and evaluating their prebiotic effect in vivo.
- 17 December 2025
- Published by FSBEI HE Voronezh State University of Engineering Technologies in Proceedings of the Voronezh State University of Engineering Technologies
- Vol. 87 (3) , 129-134
Open AccessFeatures of beer beverage technology using non-traditional raw materials
The aim of this study is to develop a technology for producing beverages using non-traditional raw materials for consumers with gastrointestinal disorders and to investigate the physicochemical properties of the resulting products. A comprehensive approach was used to conduct the study, including an analysis of scientific literature, including the potential for beer consumption by people with gastrointestinal issues, and an examination of functional beverage production technology. The study involved beverage samples produced using quinoa malt, Jerusalem artichoke powder, and berry and vegetable juices. The technological processes for producing beer beverages with an alcohol content of 2.5-3.0% by volume were studied. Physicochemical studies, namely, extract content, color, active (pH 5.2), and titratable acidity, demonstrated that all developed beverage samples meet regulatory standards for this type of product. The organoleptic properties of the beverages were found to have a balanced flavor profile, owing to the inclusion of quinoa malt, Jerusalem artichoke powder, and berry and vegetable juices such as apricot, lingonberry, pumpkin, and carrot. The study demonstrated the potential of using quinoa malt and Jerusalem artichoke powder to create specialized food products. The developed technology not only addresses the needs of certain population groups but also expands the product range by producing functional, gluten-free beverages with an improved nutrient profile. Further research could focus on optimizing flavor balance, studying the stability and shelf life of these products, and evaluating their prebiotic effect in vivo.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 16-25
Antiproliferative properties of a new plant alkaloid against cellular colorectal cancer cultures
Purpose of the study. To evaluate the antiproliferative properties of the novel alkaloid (P1) against CRC cell lines HT‑29, Caco‑2, and HCT116. Materials and methods . CRC cell lines (HCT116, HT‑29, Caco‑2) were used in the experiments. The alkaloid (P1) was isolated from Petasites hybridus (L.) G. Gaertn., B. Mey. & Scherb and identified using high-performance liquid chromatography (HPLC) and nuclear magnetic resonance spectroscopy (NMR). Cells were incubated with various concentrations of the alkaloid, and cell viability was assessed. Berberine, a well-known anticancer alkaloid, served as the reference compound. Results. The alkaloid (P1) demonstrated pronounced antiproliferative activity across all tested colorectal cancer cell lines – HCT116, HT‑29, and Caco‑2. The highest sensitivity was observed in HCT116 cells, with an IC50 value of 15.73 μmol/L after 72‑hour incubation, indicating a substantial inhibitory effect on tumor cell proliferation. Comparative analysis showed that (P1) exhibited greater cytostatic efficacy than berberine in Caco‑2 (IC50 (P1) = 54.489 ± 8.3 μmol/L vs IC50 (berb) = 193.154 ± 13.1 μmol/L) and HT‑29 cultures (IC50 (P1) = 55.375 ± 7.1 μmol/L vs IC50 (berb) = 90.22 ± 8.2 μmol/L). Conclusion. The findings indicate that the alkaloid (P1) possesses significant antiproliferative potential against colorectal cancer cell lines, underscoring its promise as a prospective anticancer agent. Notably, its superior efficacy compared with berberine highlights the relevance of further investigation. These results support continued development of (P1) as a basis for novel therapeutic agents. Future work should include detailed preclinical and clinical studies to elucidate its mechanism of action, evaluate safety and in vivo efficacy, and optimize pharmacological properties for potential clinical application.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 16-25
Antiproliferative properties of a new plant alkaloid against cellular colorectal cancer cultures
Purpose of the study. To evaluate the antiproliferative properties of the novel alkaloid (P1) against CRC cell lines HT‑29, Caco‑2, and HCT116. Materials and methods . CRC cell lines (HCT116, HT‑29, Caco‑2) were used in the experiments. The alkaloid (P1) was isolated from Petasites hybridus (L.) G. Gaertn., B. Mey. & Scherb and identified using high-performance liquid chromatography (HPLC) and nuclear magnetic resonance spectroscopy (NMR). Cells were incubated with various concentrations of the alkaloid, and cell viability was assessed. Berberine, a well-known anticancer alkaloid, served as the reference compound. Results. The alkaloid (P1) demonstrated pronounced antiproliferative activity across all tested colorectal cancer cell lines – HCT116, HT‑29, and Caco‑2. The highest sensitivity was observed in HCT116 cells, with an IC50 value of 15.73 μmol/L after 72‑hour incubation, indicating a substantial inhibitory effect on tumor cell proliferation. Comparative analysis showed that (P1) exhibited greater cytostatic efficacy than berberine in Caco‑2 (IC50 (P1) = 54.489 ± 8.3 μmol/L vs IC50 (berb) = 193.154 ± 13.1 μmol/L) and HT‑29 cultures (IC50 (P1) = 55.375 ± 7.1 μmol/L vs IC50 (berb) = 90.22 ± 8.2 μmol/L). Conclusion. The findings indicate that the alkaloid (P1) possesses significant antiproliferative potential against colorectal cancer cell lines, underscoring its promise as a prospective anticancer agent. Notably, its superior efficacy compared with berberine highlights the relevance of further investigation. These results support continued development of (P1) as a basis for novel therapeutic agents. Future work should include detailed preclinical and clinical studies to elucidate its mechanism of action, evaluate safety and in vivo efficacy, and optimize pharmacological properties for potential clinical application.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 26-35
Cytostatic effect of ricobendazole on primary cultures of soft tissue sarcomas in vitro
Soft tissue sarcomas (STS) are often resistant to treatment. The search for new antitumor compounds against STS remains an urgent task. Purpose of the study. To assess the sensitivity of primary STS cultures of various histological subtypes to albendazole sulfoxide (ricobendazole) and doxorubicin, the primary metabolite of albendazole. Materials and methods . STS tumor samples were used. The enzymatic dissociation method was used using 300 units/ml collagenase I (Thermo Fisher Scientific, USA). Ricasol® (NITA-PHARM, Russia) and Doxorubicin-LENS® (VEROPHARM, Russia) were used as test substances. Sensitivity to ricobendazole and doxorubicin was tested using the MTT test. The cultures were seeded in a 96‑well plate at 7,000 cells in DMEM medium with 10 % FSC added. After 24 h, the medium was replaced with PPS with ricobendazole in a series of two-fold dilutions from 35.5 μmol/l to 0.0347 μmol/l or doxorubicin from 10 μmol/l to 0.009 μmol/l. After 72 hours of incubation, the MTT test was performed. The cells were seeded in a 24‑well plate and cultured in PPS with 2 μmol/l ricabendazole for 72 h. Hoechst 33342 dye (Life Technologies, USA) was added to the culture at a concentration of 1 μg/ml, and photographs were taken using a LionHeart FX digital automatic microscope (BioTek Instruments Inc., USA). Results. Four primary sarcoma cultures were obtained: SAR‑1, SAR‑2, SAR‑3, and SAR‑4. SAR-1 and SAR-4. Cultures demonstrated the most rapid growth, with doubling times of 38 and 27 hours, respectively. The slowest proliferation was observed in the SAR-2 culture (doubling time 156 hours), while SAR-3 showed a doubling time of 45 hours. According to the MTT assay, the IC50 values for ricobendazole were 4.54 ± 1.2 μmol/L for SAR-1, 3.31 ± 0.7 μmol/L for SAR-3, and 1.51 ± 0.2 μmol/L for SAR-4, whereas the slowly dividing SAR-2 culture proved to be insensitive to ricobendazole. The cytostatic activity of doxorubicin was higher than that of ricobendazole. The SAR‑2 culture was the least sensitive (IC50 could not be determined), and SAR‑4 (IC50 SAR‑4 = 0.16 ± 0.01 μmol/l) was the most sensitive to the action of doxorubicin. The IC50 value of SAR‑1 = 0.64 ± 0.02 μmol/l and IC50 SAR‑3 = 1.8 ± 0.1 μmol/l. The effect of ricobendazole caused pronounced disturbances in the nuclei of SAR‑1 and SAR‑4 cultures, in SAR‑2 and SAR‑3 they were less pronounced. Conclusion. Ricobenzale had a cytostatic effect on primary STS cultures characterized by rapid cell growth, but the activity was lower than that of doxorubicin. Changes in the morphology of cells and nuclei indicated probable disturbances in the functioning of the spindle and cytoskeleton occurring under the action of this compound. Of particular interest for further research is the combination of ricobendazole with taxanes and other tubulin inhibitors.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 26-35
Cytostatic effect of ricobendazole on primary cultures of soft tissue sarcomas in vitro
Soft tissue sarcomas (STS) are often resistant to treatment. The search for new antitumor compounds against STS remains an urgent task. Purpose of the study. To assess the sensitivity of primary STS cultures of various histological subtypes to albendazole sulfoxide (ricobendazole) and doxorubicin, the primary metabolite of albendazole. Materials and methods . STS tumor samples were used. The enzymatic dissociation method was used using 300 units/ml collagenase I (Thermo Fisher Scientific, USA). Ricasol® (NITA-PHARM, Russia) and Doxorubicin-LENS® (VEROPHARM, Russia) were used as test substances. Sensitivity to ricobendazole and doxorubicin was tested using the MTT test. The cultures were seeded in a 96‑well plate at 7,000 cells in DMEM medium with 10 % FSC added. After 24 h, the medium was replaced with PPS with ricobendazole in a series of two-fold dilutions from 35.5 μmol/l to 0.0347 μmol/l or doxorubicin from 10 μmol/l to 0.009 μmol/l. After 72 hours of incubation, the MTT test was performed. The cells were seeded in a 24‑well plate and cultured in PPS with 2 μmol/l ricabendazole for 72 h. Hoechst 33342 dye (Life Technologies, USA) was added to the culture at a concentration of 1 μg/ml, and photographs were taken using a LionHeart FX digital automatic microscope (BioTek Instruments Inc., USA). Results. Four primary sarcoma cultures were obtained: SAR‑1, SAR‑2, SAR‑3, and SAR‑4. SAR-1 and SAR-4. Cultures demonstrated the most rapid growth, with doubling times of 38 and 27 hours, respectively. The slowest proliferation was observed in the SAR-2 culture (doubling time 156 hours), while SAR-3 showed a doubling time of 45 hours. According to the MTT assay, the IC50 values for ricobendazole were 4.54 ± 1.2 μmol/L for SAR-1, 3.31 ± 0.7 μmol/L for SAR-3, and 1.51 ± 0.2 μmol/L for SAR-4, whereas the slowly dividing SAR-2 culture proved to be insensitive to ricobendazole. The cytostatic activity of doxorubicin was higher than that of ricobendazole. The SAR‑2 culture was the least sensitive (IC50 could not be determined), and SAR‑4 (IC50 SAR‑4 = 0.16 ± 0.01 μmol/l) was the most sensitive to the action of doxorubicin. The IC50 value of SAR‑1 = 0.64 ± 0.02 μmol/l and IC50 SAR‑3 = 1.8 ± 0.1 μmol/l. The effect of ricobendazole caused pronounced disturbances in the nuclei of SAR‑1 and SAR‑4 cultures, in SAR‑2 and SAR‑3 they were less pronounced. Conclusion. Ricobenzale had a cytostatic effect on primary STS cultures characterized by rapid cell growth, but the activity was lower than that of doxorubicin. Changes in the morphology of cells and nuclei indicated probable disturbances in the functioning of the spindle and cytoskeleton occurring under the action of this compound. Of particular interest for further research is the combination of ricobendazole with taxanes and other tubulin inhibitors.
- 2 September 2025
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (8) , 23-26
Потенциальное прооксидантное действие нового соединения трополонового ряда на культурах клеток злокачественных опухолей
Большинство опухолевых клеток, помимо высокой активности аэробного гликолиза, также демонстрируют высокие уровни окислительного стресса. Увеличение уровня активных форм кислорода в опухолевых клетках коррелирует с агрессивностью опухолей, неблагоприятным прогнозом и возникновением резистентности к противоопухолевым лекарственным средствам. Однако повышение уровня активных форм кислорода до определенных значений может привести к гибели опухолевых клеток и, следовательно, замедлить прогрессирование опухоли. Целью исследования было проведение оценки возможного прооксидантного действия соединения 2-(1,1-диметил-1H-бензо[e]индолин- 2-ил)-5,6,7-трихлор-1,3-трополона (JO122) на культурах клеток злокачественных опухолей. Исследование проводили на клеточных культурах линии аденокарциномы толстой кишки HT-29, карциномы шейки матки HeLa и аденокарциномы легкого H1299, которые культивировали в питательной среде с добавлением JO122 в субтоксических концентрациях 3, 1,5 и 0,75 мкмоль/л в течение 1 и 24 ч. По окончании культивирования оценивали содержание активных форм кислорода путем измерения средней интенсивности флуоресценции красителя H2DCFDA (2’,7’-диxлopoдиrидpoфлyopecцeинa диацетат) (Lumiprobe, Россия) в клетке. Установлено, что соединение JO122 в протестированном диапазоне концентраций не способствует увеличению продукции активных форм кислорода в исследованных клеточных культурах. Таким образом, новое соединение трополонового ряда не обладает прооксидантной активностью и не может быть использовано для усиления окислительного стресса в опухоли.
- 2 September 2025
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (8) , 23-26
Потенциальное прооксидантное действие нового соединения трополонового ряда на культурах клеток злокачественных опухолей
Большинство опухолевых клеток, помимо высокой активности аэробного гликолиза, также демонстрируют высокие уровни окислительного стресса. Увеличение уровня активных форм кислорода в опухолевых клетках коррелирует с агрессивностью опухолей, неблагоприятным прогнозом и возникновением резистентности к противоопухолевым лекарственным средствам. Однако повышение уровня активных форм кислорода до определенных значений может привести к гибели опухолевых клеток и, следовательно, замедлить прогрессирование опухоли. Целью исследования было проведение оценки возможного прооксидантного действия соединения 2-(1,1-диметил-1H-бензо[e]индолин- 2-ил)-5,6,7-трихлор-1,3-трополона (JO122) на культурах клеток злокачественных опухолей. Исследование проводили на клеточных культурах линии аденокарциномы толстой кишки HT-29, карциномы шейки матки HeLa и аденокарциномы легкого H1299, которые культивировали в питательной среде с добавлением JO122 в субтоксических концентрациях 3, 1,5 и 0,75 мкмоль/л в течение 1 и 24 ч. По окончании культивирования оценивали содержание активных форм кислорода путем измерения средней интенсивности флуоресценции красителя H2DCFDA (2’,7’-диxлopoдиrидpoфлyopecцeинa диацетат) (Lumiprobe, Россия) в клетке. Установлено, что соединение JO122 в протестированном диапазоне концентраций не способствует увеличению продукции активных форм кислорода в исследованных клеточных культурах. Таким образом, новое соединение трополонового ряда не обладает прооксидантной активностью и не может быть использовано для усиления окислительного стресса в опухоли.
- Open Access
- 7 July 2025
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 27 (4) , 775-788
MicroRNAs and target genes as regulators of colon cancer immune signaling
Colorectal cancer (CRC) is among the most common oncological diseases in the world, associated with a high mortality rate. Recently, immunotherapeutic approaches to the treatment of CRC have been developed, which have enabled achievement of long-term and stable remission in a certain group of patients. The success of immunotherapy depends on the immune processes associated with oncogenesis in the colon. The key role in modulating immune environment of the tumor is played by the activity of genes regulating differentiation and functions of immune cells, as well as by a variety of microRNAs that perform posttranscriptional expression control of target genes. In this regard, the aim of our work was to study the expression profiles of immune-associated genes and microRNAs to determine the immune signaling mechanisms of colon cancer and search for potential therapeutic targets. The study included 18 persons (12 women, 6 men, median age – 66 years) diagnosed with colon cancer, having been treated at the National Medical Research Center of Oncology in 2018-2019. All tumors had microsatellite instability status. The transcription profiles of microRNAs and immune response genes were determined by next-generation sequencing. The study has revealed 28 differentially expressed microRNAs in the tumor tissues, including 15 microRNAs with increased expression and 13 microRNAs with decreased expression. Of the 395 genes examined, 156 were differentially expressed, including 62 genes with increased expression and 94 genes with decreased activity. Identification of cell populations based on the transcriptional pattern of tumors has discerned four types of immune cells: neutrophils, B lymphocytes, CD8+T lymphocytes, and M1 macrophages. Neutrophils were the most common cell type (16 of 18 samples). A stepwise analysis of possible relationships between transcriptional patterns allowed us to select 713 miRNA-mRNA pairs. After filtering by validated interactions, 24 such pairs were found. On this basis, a miRNA-mRNA interaction network was constructed, which could be involved into the regulation of multiple immune signaling mechanisms and cell cycle control. Most of the revealed signaling pathways contained CDK1, for which therapeutic inhibitors are known, being at different stages of clinical trials. The possibilities of influencing CDK1 described in the present work may be used for further clinical studies and development of therapeutic strategies employing selective molecular suppression of immunemediated carcinogenesis in colorectal cancer.
- 7 July 2025
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 27 (4) , 775-788
Open AccessMicroRNAs and target genes as regulators of colon cancer immune signaling
Colorectal cancer (CRC) is among the most common oncological diseases in the world, associated with a high mortality rate. Recently, immunotherapeutic approaches to the treatment of CRC have been developed, which have enabled achievement of long-term and stable remission in a certain group of patients. The success of immunotherapy depends on the immune processes associated with oncogenesis in the colon. The key role in modulating immune environment of the tumor is played by the activity of genes regulating differentiation and functions of immune cells, as well as by a variety of microRNAs that perform posttranscriptional expression control of target genes. In this regard, the aim of our work was to study the expression profiles of immune-associated genes and microRNAs to determine the immune signaling mechanisms of colon cancer and search for potential therapeutic targets. The study included 18 persons (12 women, 6 men, median age – 66 years) diagnosed with colon cancer, having been treated at the National Medical Research Center of Oncology in 2018-2019. All tumors had microsatellite instability status. The transcription profiles of microRNAs and immune response genes were determined by next-generation sequencing. The study has revealed 28 differentially expressed microRNAs in the tumor tissues, including 15 microRNAs with increased expression and 13 microRNAs with decreased expression. Of the 395 genes examined, 156 were differentially expressed, including 62 genes with increased expression and 94 genes with decreased activity. Identification of cell populations based on the transcriptional pattern of tumors has discerned four types of immune cells: neutrophils, B lymphocytes, CD8+T lymphocytes, and M1 macrophages. Neutrophils were the most common cell type (16 of 18 samples). A stepwise analysis of possible relationships between transcriptional patterns allowed us to select 713 miRNA-mRNA pairs. After filtering by validated interactions, 24 such pairs were found. On this basis, a miRNA-mRNA interaction network was constructed, which could be involved into the regulation of multiple immune signaling mechanisms and cell cycle control. Most of the revealed signaling pathways contained CDK1, for which therapeutic inhibitors are known, being at different stages of clinical trials. The possibilities of influencing CDK1 described in the present work may be used for further clinical studies and development of therapeutic strategies employing selective molecular suppression of immunemediated carcinogenesis in colorectal cancer.